Shopping Cart
Remove All
Your shopping cart is currently empty
Pro8-Oxytocin, a modified oxytocin (OXT) ligand, elicits more potent and efficacious responses at primate OXTR and induces stronger behavioral effects compared to the standard mammalian OXT ligand (Leu8-Oxytocin). It demonstrates lower efficacy than Vasopressin (AVP) at human AVPR1a, yet shows a higher efficacious response at marmoset AVPR1a [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Pro8-Oxytocin, a modified oxytocin (OXT) ligand, elicits more potent and efficacious responses at primate OXTR and induces stronger behavioral effects compared to the standard mammalian OXT ligand (Leu8-Oxytocin). It demonstrates lower efficacy than Vasopressin (AVP) at human AVPR1a, yet shows a higher efficacious response at marmoset AVPR1a [1]. |
| In vitro | Pro8-Oxytocin, at concentrations ranging from 1 nM to 10 μM, is capable of inducing calcium mobilization in CHO cells expressing the AVPR1a receptor [1]. |
| In vivo | Pro8-Oxytocin exhibits higher binding affinity for the primate oxytocin receptor (OXTR) than Leu8-Oxytocin, particularly in primates expressing Pro8-OXT and Leu8-OXT, resulting in a more potent calcium signaling response [1]. |
| Molecular Weight | 991.14 |
| Formula | C42H62N12O12S2 |
| Cas No. | 24327-19-3 |
| Smiles | C(=O)([C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@]([C@H](CC)C)(NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@@H](N)CSSC2)[H])CCC1)N4[C@H](C(NCC(N)=O)=O)CCC4 |
| Sequence | Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Pro-Gly-NH2 (Disulfide bridge: Cys1-Cys6) |
| Sequence Short | CYIQNCPPG-NH2 (Disulfide bridge: Cys1-Cys6) |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.